Cargando…

NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma

A pivotal strategy to improve NK cell-mediated antitumor activity involves the upregulation of activating ligands on tumor cells. Enhancement of NK cell-mediated recognition of multiple myeloma cells was reported by us and others showing increased surface expression of NKG2D and DNAM-1 ligands on tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fionda, Cinzia, Soriani, Alessandra, Zingoni, Alessandra, Santoni, Angela, Cippitelli, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486747/ https://www.ncbi.nlm.nih.gov/pubmed/26161387 http://dx.doi.org/10.1155/2015/178698

Ejemplares similares

Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma
por: Soriani, Alessandra, et al.
Publicado: (2013)

The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells
por: Cerboni, Cristina, et al.
Publicado: (2014)

Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation
por: Fionda, Cinzia, et al.
Publicado: (2015)

NKG2D and Its Ligands: “One for All, All for One”
por: Zingoni, Alessandra, et al.
Publicado: (2018)

NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses
por: Zingoni, Alessandra, et al.
Publicado: (2013)

Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition
por: Petillo, Sara, et al.
Publicado: (2021)

Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing
por: Vulpis, Elisabetta, et al.
Publicado: (2023)

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay
por: Abruzzese, Maria Pia, et al.
Publicado: (2016)

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
por: Fionda, Cinzia, et al.
Publicado: (2015)

Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance
por: Zingoni, Alessandra, et al.
Publicado: (2017)

GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells
por: Kosta, Andrea, et al.
Publicado: (2022)

Key Role of the CD56(low)CD16(low) Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells
por: Vulpis, Elisabetta, et al.
Publicado: (2018)

Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation
por: Fionda, Cinzia, et al.
Publicado: (2021)

Doxorubicin–Mediated miR–433 Expression on Exosomes Promotes Bystander Senescence in Multiple Myeloma Cells in a DDR–Independent Manner
por: Vulpis, Elisabetta, et al.
Publicado: (2023)

The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors
por: Abruzzese, Maria Pia, et al.
Publicado: (2019)

NKG2D Ligand Shedding in Response to Stress: Role of ADAM10
por: Zingoni, Alessandra, et al.
Publicado: (2020)

Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma
por: Niu, Chao, et al.
Publicado: (2016)

NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells
por: Petillo, Sara, et al.
Publicado: (2023)

How Mucosal Epithelia Deal with Stress: Role of NKG2D/NKG2D Ligands during Inflammation
por: Antonangeli, Fabrizio, et al.
Publicado: (2017)

Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF-kB Transcription Factor
por: Mekhloufi, Abdelilah, et al.
Publicado: (2020)

MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma
por: Zingoni, Alessandra, et al.
Publicado: (2018)

Cancer Exosomes as Conveyors of Stress-Induced Molecules: New Players in the Modulation of NK Cell Response
por: Vulpis, Elisabetta, et al.
Publicado: (2019)

Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention
por: Molfetta, Rosa, et al.
Publicado: (2019)

Hitting More Birds with a Stone: Impact of TGF-β on ILC Activity in Cancer
por: Fionda, Cinzia, et al.
Publicado: (2020)

Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them
por: Cippitelli, Marco, et al.
Publicado: (2021)

Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle‐associated MICA: Dual role in cancer immunosurveillance
por: Vulpis, Elisabetta, et al.
Publicado: (2022)

Role of NF-κB Signaling in the Interplay between Multiple Myeloma and Mesenchymal Stromal Cells
por: Cippitelli, Marco, et al.
Publicado: (2023)

Altered expression of ligands for the NKG2D and DNAM-1 activating receptors during HIV-1 infection
por: Vassena, Lia, et al.
Publicado: (2013)

Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells
por: Zitti, Beatrice, et al.
Publicado: (2017)

The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM-1 receptors
por: Veneziani, Irene, et al.
Publicado: (2019)

Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer
por: Han, Bin, et al.
Publicado: (2018)

DNAM-1 controls NK cell activation via an ITT-like motif
por: Zhang, Zhanguang, et al.
Publicado: (2015)

Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D
por: Sayitoglu, Ece Canan, et al.
Publicado: (2020)

Dynamic of Circulating DNAM-1+ Monocytes and NK Cells in Patients with STEMI Following Primary Percutaneous Coronary Intervention
por: Kumric, Marko, et al.
Publicado: (2022)

S256: HLA-E/NKG2A CHECKPOINT DRIVES MULTIPLE MYELOMA RESISTANCE TO CAR-NK THERAPY
por: Encinas, Jessica, et al.
Publicado: (2023)

Defective DNAM-1 Dependent Cytotoxicity in Hepatocellular Carcinoma-Infiltrating NK Cells
por: Mantovani, Stefania, et al.
Publicado: (2022)

Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis
por: Molfetta, Rosa, et al.
Publicado: (2017)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

Endothelial cells express NKG2D ligands and desensitize antitumor NK responses
por: Thompson, Thornton W, et al.
Publicado: (2017)

Editorial: Women in NK and innate lymphoid cell biology
por: Zingoni, Alessandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4na8dbrcev6s58khp95ppliqtn